Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas

A prospective, multicenter, open label, randomized phase III study to evaluate efficacy and safety of FFX versus CPI-613 + mFFX in patients with metastatic adenocarcinoma of the pancreas with age range of 18 to 75 years
Not Available
III
Cardin, Dana
NCT03504423
VICCGI18158

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: